Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1951 to 2000 of 3008 results for all

  1. Transcutaneous microwave ablation for severe primary axillary hyperhidrosis (HTG458)

    Evidence-based recommendations on transcutaneous microwave ablation for severe primary axillary hyperhidrosis in adults. This involves using microwaves to destroy sweat glands in the armpit.

  2. Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina (HTG464)

    Evidence-based recommendations on laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina. This involves inserting mesh to hold the uterus or the top of the vagina in place.

  3. Selective peripheral denervation for cervical dystonia (HTG51)

    Evidence-based recommendations on selective peripheral denervation for cervical dystonia. This involves cutting the nerves to the muscles of the neck through a large skin incision.

  4. Endoaortic balloon occlusion for cardiac surgery (HTG168)

    Evidence-based recommendations on endoaortic balloon occlusion for cardiac surgery. This involves inserting a tube with a balloon attached into the aorta and filling it with saline to block blood flowing from the heart so that surgery can be done.

  5. Endoscopic submucosal dissection of gastric lesions (HTG233)

    Evidence-based recommendations on endoscopic submucosal dissection (ESD) of gastric lesions. This involves inserting a thin telescope through the mouth into the stomach to view the area and removing the lesion with special equipment.

  6. Single-port laparoscopic nephrectomy (HTG278)

    Evidence-based recommendations on single-port laparoscopic nephrectomy. This involves removing the kidney using several small incisions (laparoscopy).

  7. Arthroscopic femoro–acetabular surgery for hip impingement syndrome (HTG273)

    Evidence-based recommendations on arthroscopic femoro-acetabular surgery for hip impingement syndrome. This involves removing some of the cartilage or bone, with the aim of reshaping the joint surface.

  8. Percutaneous tibial nerve stimulation for faecal incontinence (HTG263)

    Evidence-based recommendations on percutaneous tibial nerve stimulation (PTNS) for faecal incontinence. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current through the needle to the nerves that control bowel function.

  9. Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult (MIB53)

    NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .

  10. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  11. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  12. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

  13. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTG664)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.

  14. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (HTG498)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

  15. Teduglutide for treating short bowel syndrome (TA804)

    Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.

  16. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

  17. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.

  18. Balloon dilation for chronic eustachian tube dysfunction (HTG534)

    Evidence-based recommendations on balloon dilation for chronic eustachian tube dysfunction in adults and children. This involves using a balloon filled with saline to widen the eustachian tube.

  19. Urinary tract infection (lower). Patient decision aid on cystitis: taking an antibiotic

    other people in the future, for cystitis or other infections. c NICE 2022. All rights reserved. Subject to Notice of rights.

  20. Artificial intelligence for analysing CT brain scans (MIB207)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .

  21. AcQMap for mapping the heart atria to target ablation treatment for arrhythmias (MIB246)

    NICE has developed a medtech innovation briefing (MIB) on AcQMap for mapping the heart atria to target ablation treatment for arrhythmias .

  22. The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)

    NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy

  23. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

  24. Non-Hodgkin's lymphoma: diagnosis and management (NG52)

    This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

  25. Bronchiolitis in children: diagnosis and management (NG9)

    This guideline covers diagnosing and managing bronchiolitis in babies and children. It aims to help healthcare professionals diagnose bronchiolitis and identify if babies and children should be cared for at home or in hospital. It describes treatments and interventions that can be used to help with the symptoms of bronchiolitis.

  26. Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)

    Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.

  27. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

  28. Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

    Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults.

  29. Bair Hugger for measuring core temperature during perioperative care (MIB99)

    NICE has developed a medtech innovation briefing (MIB) on Bair Hugger for measuring core temperature during perioperative care .

  30. Our partners

    NICE's partners

  31. Fallopian tube recanalisation by guidewire (HTG44)

    Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this does not unblock it, using a guidewire.

  32. How we support healthtech commissioning

    savings. Understand our different types of healthtech guidance . View all NICE healthtech guidance. Planning and implementation support...

  33. Patisiran for treating hereditary transthyretin amyloidosis (HST10)

    Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.

  34. Faricimab for treating wet age-related macular degeneration (TA800)

    Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

  35. Fertility problems: assessment and treatment (NG257)

    This guideline covers diagnosing and treating health-related fertility problems. It aims to reduce variation in practice and improve how fertility problems are investigated and managed.

  36. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.

  37. Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)

    Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.

  38. Hepatitis B (QS65)

    This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.

  39. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  40. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.

  41. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

  42. Urinary tract infection in children and young people (QS36)

    This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.

  43. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

  44. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

  45. Otovent nasal balloon for otitis media with effusion (MIB59)

    NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion

  46. Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing (HTG479)

    Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.

  47. Endoscopic thoracic sympathectomy for primary facial blushing (HTG331)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.

  48. Percutaneous vertebroplasty (HTG3)

    Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.

  49. Care of dying adults in the last days of life (QS144)

    This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement.

  50. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .